SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 23, 2007 (August 17, 2007)
Date of Report (Date of earliest event reported)
DELCATH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-16133 | 06-1245881 |
| (State or other jurisdiction | (Commission File No.) | (IRS Employer |
| of incorporation) | Identification No.) |
1100 Summer Street
Stamford, CT 06905
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (203) 323-8668
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On August 20, 2007, Delcath Systems, Inc. (the “Company”) announced the resignation of Dr. Samuel Herschkowitz as a member of its Board of Directors, effective August 17, 2007. The resignation letter submitted by Dr. Herschkowitz did not reference any disagreement with the Company on any matter relating to the Company’s operations, policies and practices. Dr. Herschkowitz will continue to serve as a consultant to the Company through the end of the year.
A copy of the press release announcing Dr. Herschkowitz’s resignation is attached hereto as Exhibit 99.1.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS. | |
| (a) | None. | |
| (b) | None. | |
| (c) | None. | |
| (d) | Exhibits | |
| 99.1 | Press Release entitled “Samuel Herschkowitz, M.D. Resigns as Director of Delcath,” dated August 20, 2007. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.
| Dated: August 23, 2007 | DELCATH SYSTEMS, INC. | |||
| By: | /s/ Richard L. Taney | |||
| Name: Richard L. Taney | ||||
| Title: Chief Executive Officer | ||||
EXHIBIT INDEX
| EXHIBIT | ||
| NUMBER | DESCRIPTION | |
| 99.1 | Press Release entitled “Samuel Herschkowitz, M.D. Resigns as Director of Delcath,” dated August 20, 2007. | |
 |
|
| Company Contact: | Investor Relations Contacts: |
| Delcath Systems, Inc. | Lippert/Heilshorn & Associates, Inc. |
| Richard Taney | Anne Marie Fields |
|
(203) 323-8668
|
(afields@lhai.com) |
| www.delcath.com | (212) 838-3777 |
| Bruce Voss | |
| (bvoss@lhai.com) | |
| (310) 691-7100 | |
| www.lhai.com |
SAMUEL HERSCHKOWITZ, M.D. RESIGNS AS DIRECTOR OF DELCATH
STAMFORD, Conn. (August 20, 2007) – Delcath Systems, Inc. (Nasdaq: DCTH) today announced that Dr. Samuel Herschkowitz has resigned as a director of the company, effective August 17th 2007. Dr. Herschkowitz will continue to serve as a consultant to Delcath Systems through the end of the year in order to complete several key projects currently underway. His decision to leave the Delcath Board was based on the need to devote time to new professional activities as well as the necessity to devote more time to family matters.
Dr. Harold Koplewicz, Chairman of the Board of Directors of Delcath Systems, commented, “We would all like to thank Sam for his long and dedicated service to Delcath and wish him the best in his personal and future professional pursuits.”
Richard Taney, President and Chief Executive Officer of Delcath Systems, added, “We appreciate Sam’s long and committed service to our company. His leadership and service over the past 18 years as an executive and a director has had a meaningful impact on the direction and evolution of our company, and I am grateful for his help and counsel over the past eight months. We wish him every success in his future endeavors.”
About Delcath Systems, Inc.
Delcath Systems is the developer of percutaneous perfusion technology for organ- or region-specific delivery of therapeutic and chemotherapeutic agents. The Delcath system is currently being tested with the drug melphalan in a Phase III trial of patients with metastatic ocular and cutaneous melanoma in the liver, and a Phase II trial of patients with primary liver cancers and metastatic tumors in the liver from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website www.delcath.com